← All trials

NCT06603688

Phase 4Interventional

Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

View on ClinicalTrials.gov ↗

Timeline

Start date
Nov 20, 2023
Primary completion
Nov 1, 2024
Completion date
Dec 1, 2024
First posted
Sep 19, 2024
Last posted
Sep 19, 2024
Enrollment
548
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.